Medicus Pharma Ltd. has announced a non-binding letter of intent (LOI) with Reliant AI Inc. to develop an AI-driven clinical data analytics platform aimed at optimizing clinical trial execution. This collaboration is poised to leverage Reliant AI’s generative AI capabilities to provide data-driven insights that could significantly enhance the efficiency and effectiveness of clinical trials.
Reliant AI, founded by experts from DeepMind and Google Brain, specializes in automating data-intensive workflows, thereby enabling biopharma teams to make informed, evidence-based decisions more quickly. The proposed platform will integrate Reliant’s AI technology with Medicus’ extensive clinical and operational datasets, focusing initially on dynamic site selection and patient stratification for the upcoming Teverelix clinical study set to begin in 2026.
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus, emphasized that this strategic partnership represents a critical step toward deploying advanced analytics to enhance clinical development’s efficiency and predictability. By utilizing AI-enabled modeling alongside their clinical data, Medicus aims to refine trial execution and improve patient selection, ultimately paving the way for a broader data-driven approach in clinical development.
Get started today with Solo access →
